Shots:

• Tum Bio to receive $1M upfront- up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical trials
• The focus of the agreement is to develop and commercialize NCE401- a TGF-beta inhibitor in the fields of respiratory diseases
•  NCE401 is a preclinical candidate used for inhibiting transforming growth factor beta (TGF-β) pathway- indicated for fibrotic diseases including pulmonary fibrosis

Ref: Business Korea | Image: The Investors